Plain-English translation of NCT05139017 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new medication called combined with standard chemotherapy drugs to treat a serious type of blood cancer called diffuse large B-cell lymphoma (DLBCL) that has returned or stopped responding to previous treatments. Researchers want to know whether adding this medication to standard chemotherapy helps patients live longer without their cancer getting worse. The study will compare people who receive the medication plus chemotherapy with people who receive chemotherapy alone.
People with DLBCL that comes back after initial treatment or doesn't respond to treatment options often have limited choices and poor outcomes. This trial is looking for ways to improve treatment for these patients by combining a new targeted therapy with existing chemotherapy drugs.
You likely qualify if…
You likely don't qualify if…
Participants will receive intravenous infusions (injections into the vein) once every 3 weeks for up to 6 cycles of treatment. Each treatment cycle includes the new medication combined with chemotherapy drugs given on the first day of the cycle. Participants will have regular doctor visits and blood tests to monitor how well the treatment is working and to watch for any side effects. The study is still recruiting patients, so if you're interested, you would need to meet the eligibility criteria and be evaluated by the study team.
AI-generated summary from trial data · Aug 25, 2026 · Not medical advice
United States